Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.39 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769046 | 0.99 | SYK (0.46) | SYKJAK2LRRK2GRM4MYLK4 | |
| SCHEMBL3766184 | 0.90 | GAA (0.47) | LRRK2GRM4 | |
| SCHEMBL3774600 | 0.80 | LRRK2 (0.44) | LRRK2GRM4 | |
| SCHEMBL3763899 | 0.76 | GRM4 (0.51) | LRRK2GRM4 | |
| SCHEMBL3766328 | 0.76 | IGF1R (0.46) | LRRK2 | |
| SCHEMBL3775329 | 0.76 | LRRK2 (0.61) | LRRK2GRM4 | |
| SCHEMBL3769241 | 0.76 | CDK2 (0.48) | SYKJAK2CLK4STK17ATBK1 | |
| SCHEMBL3774961 | 0.76 | CCNE1 (0.48) | JAK2LRRK2GRM4CLK4TBK1 | |
| SCHEMBL3774496 | 0.76 | GRM5 (0.47) | LRRK2GRM4 | |
| SCHEMBL3774932 | 0.75 | LRRK2 (0.66) | SYKJAK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | SYK 2282/4885JAK2 1557/4885LRRK2 2309/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | SYK 2298/4885JAK2 1492/4885LRRK2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.